CTAG2 and prostate carcinoma: Both NY-ESO-1 and LAGE-1 were broadly expressed at various levels and across a large number of tumor cell lines, including melanoma, myeloma, mesothelioma, lung, ovarian, and prostate cancer; among the tumor cell lines tested, only the colon cancer cell line Colo205 and the colorectal carcinoma HCT116 were negative for both antigens (Table 1 and Supplementary Table 2).